Indegene's Q3 FY26: AI-Powered Growth and Strategic Expansion

Indegene Limited, a prominent player in the life sciences commercialization sector, has reported a robust performance for the third quarter of fiscal year 2026, ending December 31, 2025. The company delivered a strong top-line growth, with revenue from operations reaching INR 942.1 Crore. This represents an impressive 30.8% year-on-year (YoY) increase and a 17.1% quarter-on-quarter (QoQ) growth in INR terms. A significant highlight of the quarter was Indegene crossing the $100 million revenue mark for the first time, underscoring its expanding scale and market penetration. While the adjusted EBITDA saw healthy growth, the Profit After Tax (PAT) remained flat QoQ and declined 6.5% YoY, primarily due to one-time expenses and higher non-cash amortization charges associated with recent strategic acquisitions.

Indegene's growth narrative is deeply intertwined with its strategic focus on artificial intelligence (AI) and deepening client relationships. The company's revenue per employee has now surpassed the $70,000 annual mark, which management identifies as the highest in the industry. This metric highlights the tangible impact of technology and AI in enhancing productivity and efficiency across its operations. The client base expanded significantly, with active clients growing to 86 from 76 in the previous quarter. More notably, the number of clients contributing over$1 million in revenue increased to 52 from 40, reinforcing the depth and value of Indegene's client engagements. The company also secured several breakthrough deals, leveraging its proven execution strength with AI to deliver differentiated and measurable outcomes for clients.

Strategic Acquisitions and AI Integration

A key development during the quarter was the successful completion of two strategic acquisitions: BioPharm, a US-focused life sciences omnichannel business, and Warn & Co., a UK-based consulting firm. These acquisitions are pivotal in deepening Indegene's domain expertise and expanding its high-value capabilities. The integration of BioPharm's IT, HR, and finance services is progressing as planned, with completion expected by March 31, 2026. The technology IT integration is also on track to conclude by year-end. Joint business development efforts have already yielded positive results, including two omnichannel wins with large Indegene customers, integrating BioPharm's capabilities.

Indegene's commitment to AI is evident in its dual-pronged Gen AI strategy, designed to accelerate value for clients today while building for tomorrow. This strategy involves extending the capabilities of existing products with new Gen AI features, embedding these features for immediate value, building new avenues with platforms like CORTEX (a unified platform for Knowledge Engineering), and expanding with Gen AI-first products such as the Content Super App and Medical Writing Platform. Management highlighted that AI is creating significant productivity gains across both commercial and medical segments, enabling the company to deliver more value and penetrate deeper into adjacent spend areas.

Segmental Performance and Client Focus

The company's revenue from service offerings demonstrates a stable business mix. The Enterprise Commercial Solutions segment contributed 71.0% of the total revenue, followed by Enterprise Medical Solutions at 25.3%, and Others at 3.7%. Geographically, North America remains the largest contributor at 71.8%, with Europe at 25.5%, India at 0.4%, and Rest of World (RoW) at 2.3%. The concall transcript also revealed a strategic re-segmentation, with Brand Activation and BioPharm now integrated into the Enterprise Commercial Segment, reflecting the blurring lines between these business areas and the company's long-term vision for scaling its enterprise business.

Management emphasized its focus on deeper engagement with large pharma customers. Three of Indegene's top five customers now exceed $25 million in annual revenue, and 52 customers have surpassed the$1 million annual mark. This indicates a successful strategy of growing existing accounts and securing strong deal wins, including a $20 million TCV business with a midsized biotech company and a$7.5 million TCV deal for global pharmacovigilance workflows. These engagements are expected to yield significant annual revenues, with some starting to accrue from Q2 FY27.

Outlook and Financial Health

Despite the short-term impact on PAT, Indegene's management expressed confidence in the company's financial trajectory. They anticipate EBITDA margins to begin sequential improvement from Q1 FY27 and to return to approximately 20% over the next 6 to 8 quarters. Amortization charges are expected to remain elevated for the next three quarters before gradually reducing from Q3 FY27. The company maintains a healthy cash and investment position of INR 1,395.4 Crore, net of acquisition outflows, with strong cash generation continuing to strengthen its balance sheet.

Indegene's Q3 FY26 performance reflects a company in a strong growth phase, strategically leveraging AI and targeted acquisitions to expand its market footprint and deepen client relationships. The management's proactive approach to integrating new capabilities and focusing on high-value engagements positions Indegene for sustained profitable growth in the dynamic life sciences industry. The transient impacts on PAT are viewed as short-term effects of long-term strategic investments, with a clear path outlined for margin recovery and continued expansion.